Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors like Novo growth, but can it continue?

This article was originally published in Scrip

Executive Summary

Since 4 August 2014, traders on the stock market have indicated that GlaxoSmithKline is worth less than Novo Nordisk ($112.5bn versus $116.5bn at the end of trading on 12 August, respectively). This has nothing to with current size and performance (Figure 1): GSK is a much bigger company, with revenue 2.8 times that of Novo and net profit (earnings) more than 2.3 times as big.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026055

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel